Related Experiment Video

Updated: Aug 20, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Morphoproteomic portrait of the mTOR pathway in mesenchymal chondrosarcoma

Robert E Brown1

  • 1Division of Laboratory Medicine, Geisinger Medical Center, Danville, PA 17822-0131, USA. rebrown@geisinger.edu

Annals of Clinical and Laboratory Science
|January 15, 2005
PubMed

Insights

Morphoproteomics uses immunohistochemistry to map tumor molecular circuitry, identifying potential therapeutic targets. This study applies this method to explore the mTOR pathway in mesenchymal chondrosarcoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Proteomics

Background:

  • Morphoproteomics integrates protein expression and activation states.
  • Identifying molecular targets is crucial for tumor therapy.
  • The mTOR pathway is implicated in various cancers.

Purpose of the Study:

  • To define and illustrate morphoproteomics.
  • To apply morphoproteomics to investigate the mTOR pathway.
  • To analyze mesenchymal chondrosarcoma.

Main Methods:

  • Immunohistochemistry for protein identification.
  • Assessing protein activation (translocation, phosphorylation).
  • Correlative expression analysis.

Main Results:

  • Demonstrated the utility of morphoproteomics.
  • Depicted the mTOR pathway's molecular circuitry in mesenchymal chondrosarcoma.
  • Identified potential therapeutic targets within the pathway.

Conclusions:

  • Morphoproteomics is a powerful tool for dissecting tumor molecular landscapes.
  • This approach can reveal critical pathways like mTOR in specific tumor types.
  • Findings may guide targeted therapeutic strategies for mesenchymal chondrosarcoma.

More Related Videos

MeRIP-qPCR Assay for Detecting m6A Modification Levels of Specific RNA in Osteosarcoma Cells05:16

MeRIP-qPCR Assay for Detecting m6A Modification Levels of Specific RNA in Osteosarcoma Cells

Published on: December 30, 2025

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...